Trials / Unknown
UnknownNCT03631589
MSC for Severe aGVHD
Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the second-line therapies.The mesenchymal stem cells (MSCs) possess extensive immunomodulatory properties and are very promising to rescue the refractory aGVHD.This study aims to assess the efficacy and safety of MSCs for the treatment of the refractory aGVHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MSCs | mesenchymal stem cells therapy |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2019-12-01
- Completion
- 2021-12-01
- First posted
- 2018-08-15
- Last updated
- 2018-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03631589. Inclusion in this directory is not an endorsement.